180 related articles for article (PubMed ID: 18459658)
1. [What are the biomarkers of atherosclerosis and cardiovascular risk?].
Riesen WF
Rev Med Suisse; 2008 Mar; 4(148):636-8, 640-3. PubMed ID: 18459658
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
Ridker PM
J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
[TBL] [Abstract][Full Text] [Related]
3. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
Koenig W
Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
[TBL] [Abstract][Full Text] [Related]
4. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation.
Ferri N; Paoletti R; Corsini A
Curr Opin Lipidol; 2006 Oct; 17(5):495-501. PubMed ID: 16960497
[TBL] [Abstract][Full Text] [Related]
6. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
7. New cardiovascular risk factors exist, but are they clinically useful?
Wang TJ
Eur Heart J; 2008 Feb; 29(4):441-4. PubMed ID: 18276617
[TBL] [Abstract][Full Text] [Related]
8. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease.
Hurks R; Peeters W; Derksen WJ; Hellings WE; Hoefer IE; Moll FL; de Kleijn DP; Pasterkamp G
Thromb Haemost; 2009 Jan; 101(1):48-54. PubMed ID: 19132188
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for cardiovascular disease: challenges and future directions.
May A; Wang TJ
Trends Mol Med; 2008 Jun; 14(6):261-7. PubMed ID: 18487087
[TBL] [Abstract][Full Text] [Related]
12. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for prediction of cardiovascular events.
Ridker PM; Cook NR
N Engl J Med; 2007 Apr; 356(14):1472-3; author reply 1474-5. PubMed ID: 17415901
[No Abstract] [Full Text] [Related]
14. New predictors of adverse cardiovascular events following vascular surgery.
van Lammeren GW; de Vries JP; Vink A; de Kleijn DP; Moll FL; Pasterkamp G
Semin Cardiothorac Vasc Anesth; 2010 Jun; 14(2):148-53. PubMed ID: 20478956
[TBL] [Abstract][Full Text] [Related]
15. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
16. Developing and assessing cardiovascular biomarkers.
Dadu RT; Nambi V; Ballantyne CM
Transl Res; 2012 Apr; 159(4):265-76. PubMed ID: 22424430
[TBL] [Abstract][Full Text] [Related]
17. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
18. [New biomarkers for cardiovascular risk evaluation].
Chironi G
Rev Prat; 2012 Jun; 62(6):783-5. PubMed ID: 22838270
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for prediction of cardiovascular events.
Becker DM; Mora S; Goff DC
N Engl J Med; 2007 Apr; 356(14):1473; author reply 1474-5. PubMed ID: 17415902
[No Abstract] [Full Text] [Related]
20. Role of ezetimibe in the management of patients with atherosclerosis.
Hamilton P
Coron Artery Dis; 2009 Mar; 20(2):169-74. PubMed ID: 19106797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
